Lee Jin Hwa, Cho Michael H, Hersh Craig P, McDonald Merry-Lynn N, Wells J Michael, Dransfield Mark T, Bowler Russell P, Lynch David A, Lomas David A, Crapo James D, Silverman Edwin K
1 Channing Division of Network Medicine, and.
Am J Respir Cell Mol Biol. 2015 Mar;52(3):365-76. doi: 10.1165/rcmb.2014-0210OC.
Pulmonary hypertension is associated with advanced chronic obstructive pulmonary disease (COPD), although pulmonary vascular changes occur early in the course of the disease. Pulmonary artery (PA) enlargement (PAE) measured by computed tomography correlates with pulmonary hypertension and COPD exacerbation frequency. Genome-wide association studies of PAE in subjects with COPD have not been reported. To investigate whether genetic variants are associated with PAE within subjects with COPD, we investigated data from current and former smokers from the COPDGene Study and the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study. The ratio of the diameter of the PA to the diameter of the aorta (A) was measured using computed tomography. PAE was defined as PA/A greater than 1. A genome-wide association study for COPD with PAE was performed using subjects with COPD without PAE (PA/A ≤ 1) as a control group. A secondary analysis used smokers with normal spirometry as a control group. Genotyping was performed on Illumina platforms. The results were summarized using fixed-effect meta-analysis. Both meta-analyses revealed a genome-wide significant locus on chromosome 15q25.1 in IREB2 (COPD with versus without PAE, rs7181486; odds ratio [OR] = 1.32; P = 2.10 × 10(-8); versus smoking control subjects, rs2009746; OR = 1.42; P = 1.32 × 10(-9)). PAE was also associated with a region on 14q31.3 near the GALC gene (rs7140285; OR = 1.55; P = 3.75 × 10(-8)). Genetic variants near IREB2 and GALC likely contribute to genetic susceptibility to PAE associated with COPD. This study provides evidence for genetic heterogeneity associated with a clinically important COPD vascular subtype.
肺动脉高压与晚期慢性阻塞性肺疾病(COPD)相关,尽管肺血管变化在疾病进程早期就已出现。通过计算机断层扫描测量的肺动脉(PA)增粗(PAE)与肺动脉高压及COPD急性加重频率相关。尚未有关于COPD患者PAE的全基因组关联研究报道。为了研究基因变异是否与COPD患者的PAE相关,我们调查了来自COPDGene研究以及COPD纵向评估以识别预测替代终点研究中的现吸烟者和既往吸烟者的数据。使用计算机断层扫描测量PA直径与主动脉(A)直径的比值。PAE定义为PA/A大于1。以无PAE(PA/A≤1)的COPD患者作为对照组,对COPD合并PAE进行全基因组关联研究。二次分析使用肺功能正常的吸烟者作为对照组。在Illumina平台上进行基因分型。结果采用固定效应荟萃分析进行总结。两项荟萃分析均显示,IREB2基因所在的15q25.1染色体上存在一个全基因组显著位点(COPD合并与未合并PAE,rs7181486;比值比[OR]=1.32;P=2.10×10⁻⁸;与吸烟对照受试者相比,rs2009746;OR=1.42;P=1.32.10×10⁻⁹)。PAE还与GALC基因附近14q31.3区域相关(rs7140285;OR=1.55;P=3.75×10⁻⁸)。IREB2和GALC附近的基因变异可能导致与COPD相关的PAE遗传易感性。本研究为与临床上重要的COPD血管亚型相关的遗传异质性提供了证据。